Nimotuzumab combo after pancreatic cancer surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests adding nimotuzumab (a targeted therapy) to standard chemotherapy for people whose pancreatic cancer was completely removed with surgery. The goal is to see if this combination helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove all visible pancreatic cancer.
- Cancer has not spread to other parts of the body.
- You are in generally good health (able to do daily activities without help).
- Your liver, kidneys, bone marrow, and heart function are adequate.
- You have not previously received any treatment (like chemo or radiation) for this cancer.
- You are not allergic to the drugs used in this study.
- If you can become pregnant, you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (nimotuzumab and GX) given after surgery for pancreatic cancer. The goal is to see if this treatment helps prevent the cancer from coming back. It is for people who had their entire tumor removed and have not had prior cancer treatment.
This trial tests a new chemotherapy combination (HR070803 plus two other drugs) given after surgery to see if it prevents pancreatic cancer from coming back better than the current standard treatment.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
This trial tests combining a targeted drug (nimotuzumab) with two chemotherapy drugs (nab-paclitaxel and gemcitabine) before and after surgery for pancreatic cancer that can be surgically removed but has high-risk features or is borderline resectable. The goal is to see if this approach improves outcomes.
This trial tests combining nimotuzumab with chemotherapy (nab-paclitaxel and gemcitabine) after surgery to prevent pancreatic cancer from returning. It is for people whose tumors have a protein called EGFR, and whose cancer was removed with clear or close margins.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.